Yuwonsang, CEO of Yuyu Pharma, Visiting Germany: "Positive Response to New Dry Eye Drug... Accelerating European Market Entry"

Attended BioEurope and CPHI Consecutively

Yoo Won-sang, CEO of Yuyu Pharma (right), is meeting with local officials at 'BioEurope' held in Leipzig, Germany.
[Photo by Yuyu Pharma]

[Asia Economy Reporter Lee Gwan-joo] Yoo Won-sang, CEO of Yuyu Pharma, will personally attend a large-scale pharmaceutical and bio conference held in Europe to advance efforts for entering the European market with new drug pipelines.

Yuyu Pharma announced on the 25th that CEO Yoo will consecutively attend 'BioEurope' followed by 'CPHI'.

CEO Yoo will introduce the dry eye new drug pipeline 'YP-P10', which is currently in Phase 2 clinical trials in the United States, at BioEurope currently underway in Leipzig, Germany, and at CPHI to be held in Frankfurt from the 1st to the 3rd of next month.

CEO Yoo plans to focus on meeting clinical research organizations (CROs) and medical and pharmaceutical professors to prepare for European clinical trials of YP-P10. He will also discuss business cooperation with global pharmaceutical companies and meet with European regulatory affairs (RA) and drug price registration officials. Additionally, he will discuss the development of improved drugs in the soft capsule field, an area where Yuyu Pharma has strengths.

CEO Yoo said, "Starting with attending this conference, we will sequentially carry out preliminary activities for Yuyu Pharma's entry into Europe. We have received positive feedback on the new drug pipelines currently in progress from European pharmaceutical and bio industry stakeholders."

This content was produced with the assistance of AI translation services.